Dare Bioscience, Inc. DARE 深 滬
已收盤 04-02 16:00:00 美东时间
1.74
-0.160
-8.42%
華盛通- 最 高1.865
- 今 開1.85
- 成交量 9.44万股
- 最 低 1.695
- 昨 收 1.90
- 總市值 2533.35万
- 52周最高 9.19
- 市盈率 靜 --
- 換手率 0.65%
- 52周最低 1.27
- 委 比 86.99%
- 總股本 1455.95万
- 歷史最高 76.44
- 量 比 0.43
- 振 幅 8.95%
- 歷史最低 1.27
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dare Bioscience Q4 EPS $(0.02) Beats $(0.43) Estimate, Sales $1.024M Beat $375.750K Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.43) by 95.37 percent. This is a 96.92 percent increase over losses of $(0.65) per share from
03-27 04:05
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
Daré Bioscience Gets ~$2M Funding From National Institutes Of Health's Division For Its Intravaginal Ring DARE-PTB1 For Prevention Of Preterm Birth
Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced receipt of a revised
03-16 20:08
Daré Bioscience Announces FDA Clears Its Investigational New Drug Application For DARE-HPV To Initiate Planned Phase 2 Clinical Study For Papillomavirus Infection Treatment
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that the U.S. Food and
02-23 21:04
Daré Bioscience Launches First Evidence-Backed Topical Sildenafil Cream For Women
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in
2025-12-10 21:08
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
2025-12-03 09:58
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $12 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Dare Bioscience (NASDAQ:DARE) with a Buy and maintains $12 price target.
2025-12-02 19:57
Daré Bioscience Regains Full Rights To Ovaprene As Bayer Terminates License Agreement
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that all rights to
2025-12-01 21:10
Daré Bioscience Receives About $3.6M Payment Under Existing Grant Agreement With Gates Foundation
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it has received
2025-11-24 21:04
电话会总结 ｜ Daré Bioscience(DARE)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Daré Bioscience业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** 截至第三季度末，公司现金及现金等价物约为2,300万美元，营运资金约为380万美元。 **融资活动：** 第三季度通过普通股销售获得约1,870万美元净收益，同时收到730万美元的政府资助资金。 **费用支出：** - 一般管理费用（G&A）为250万美元 - 研发费用（R&D）为120万美元 ## 2. 财务指标变化 **费用同比变化：** - 一般管理费用同比增长25%（从2024年第三季度的200万美元增至250万美元），主要由于
2025-11-14 12:19
